Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Editorial Board Members’ Collection Series: “Molecular Research in Alzheimer’s Disease”
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Editorial Board Members’ Collection Series: “Molecular Research in Alzheimer’s Disease”

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: closed (20 November 2024) | Viewed by 7412

Special Issue Editors

Dr. Julián Benito-León

E-Mail Website
Guest Editor
Department of Medicine, Universidad Complutense, Pl. de Ramón y Cajal, s/n, 28040 Madrid, Spain
Interests: neurodegenerative diseases; pathogenesis; neuroepidemiology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Amal Kaddoumi

E-Mail Website
Guest Editor
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, Georgia 30912, United States
Interests: Alzheimer's disease; cerebral amyloid angiopathy; blood-brain barrier; neuroinflammation; amyloid-β
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Mercè Pallàs

E-Mail Website
Guest Editor
Pharmacology Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Neuroscience, Universitat de Barcelona, 08028 Barcelona, Spain
Interests: ageing; neurodegeneration; Alzheimer's disease; neuropharmacology; oxidative stress; mitochondria; proteostasis; epigenetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The collection “Molecular Research in Alzheimer’s disease” in the International Journal of Molecular Sciences (IJMS) offers a comprehensive review of cutting-edge studies addressing the molecular underpinnings of Alzheimer’s Disease (AD). Alzheimer’s, a devastating neurodegenerative disorder, presents complex multifactorial etiologies, and this series sheds light on the intricate interplay of the genetic, proteomic, and metabolic pathways implicated in its pathogenesis. This collection unveils potential therapeutic targets by exploring the role of beta-amyloid accumulation, tau protein phosphorylation, neuroinflammation, and oxidative stress. Furthermore, it delves into novel biomarkers for early AD diagnosis, providing a beacon of hope for timely interventions. The featured studies harness advanced molecular techniques, from genomic sequencing to proteomic analyses, underscoring the importance of a multidisciplinary approach to decipher the complexities of AD. This series is a pivotal resource for researchers, clinicians, and students, facilitating a deeper understanding of AD’s molecular landscape and driving innovative diagnosis, prevention, and treatment strategies. Through this compilation, the IJMS Editorial Board Members reiterate the significance of molecular research in shaping the future landscape of AD management.

Dr. Julián Benito-León
Prof. Dr. Amal Kaddoumi
Prof. Dr. Mercè Lliberia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer’s disease (AD)
  • molecular underpinnings
  • neurodegenerative disorder
  • beta-amyloid accumulation
  • tau protein phosphorylation
  • neuroinflammation
  • oxidative stress
  • therapeutic targets
  • biomarkers
  • early diagnosis
  • genomic sequencing
  • proteomic analyses
  • multidisciplinary approach
  • prevention
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 4950 KiB  
Article
Dual Role of NMDAR Containing NR2A and NR2B Subunits in Alzheimer’s Disease
by Iu Raïch, Jaume Lillo, Joan Biel Rebassa, Toni Capó, Arnau Cordomí, Irene Reyes-Resina, Mercè Pallàs and Gemma Navarro
Int. J. Mol. Sci. 2024, 25(9), 4757; https://doi.org/10.3390/ijms25094757 - 26 Apr 2024
Cited by 2 | Viewed by 2108
Abstract
Alzheimer’s disease (AD) is the main cause of dementia worldwide. Given that learning and memory are impaired in this pathology, NMDA receptors (NMDARs) appear as key players in the onset and progression of the disease. NMDARs are glutamate receptors, mainly located at the [...] Read more.
Alzheimer’s disease (AD) is the main cause of dementia worldwide. Given that learning and memory are impaired in this pathology, NMDA receptors (NMDARs) appear as key players in the onset and progression of the disease. NMDARs are glutamate receptors, mainly located at the post-synapse, which regulate voltage-dependent influx of calcium into the neurons. They are heterotetramers, and there are different subunits that can be part of the receptors, which are usually composed of two obligatory GluN1 subunits plus either two NR2A or two NR2B subunits. NR2A are mostly located at the synapse, and their activation is involved in the expression of pro-survival genes. Conversely, NR2B are mainly extrasynaptic, and their activation has been related to cell death and neurodegeneration. Thus, activation of NR2A and/or inactivation of NR2B-containing NMDARS has been proposed as a therapeutic strategy to treat AD. Here, we wanted to investigate the main differences between both subunits signalling in neuronal primary cultures of the cortex and hippocampus. It has been observed that Aβ induces a significant increase in calcium release and also in MAPK phosphorylation signalling in NR2B-containing NMDAR in cortical and hippocampal neurons. However, while NR2A-containing NMDAR decreases neuronal death and favours cell viability after Aβ treatment, NR2B-containing NMDAR shows higher levels of cytotoxicity and low levels of neuronal survival. Finally, it has been detected that NMDAR has no effect on pTau axonal transport. The present results demonstrate a different role between GluNA and GluNB subunits in neurodegenerative diseases such as Alzheimer’s. Full article
(This article belongs to the Special Issue Editorial Board Members’ Collection Series: “Molecular Research in Alzheimer’s Disease”)
►▼ Show Figures

Figure 1

Review

Jump to: Research

44 pages, 2827 KiB  
Review
Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and Prognostics
by Mrinmay Dhauria, Ritwick Mondal, Shramana Deb, Gourav Shome, Dipanjan Chowdhury, Shramana Sarkar and Julián Benito-León
Int. J. Mol. Sci. 2024, 25(20), 10911; https://doi.org/10.3390/ijms252010911 - 10 Oct 2024
Cited by 6 | Viewed by 4752
Abstract
Alzheimer’s disease (AD), the most prevalent form of dementia, is expected to rise dramatically in incidence due to the global population aging. Traditional diagnostic approaches, such as cerebrospinal fluid analysis and positron emission tomography, are expensive and invasive, limiting their routine clinical use. [...] Read more.
Alzheimer’s disease (AD), the most prevalent form of dementia, is expected to rise dramatically in incidence due to the global population aging. Traditional diagnostic approaches, such as cerebrospinal fluid analysis and positron emission tomography, are expensive and invasive, limiting their routine clinical use. Recent advances in blood-based biomarkers, including amyloid-beta, phosphorylated tau, and neurofilament light, offer promising non-invasive alternatives for early AD detection and disease monitoring. This review synthesizes current research on these blood-based biomarkers, highlighting their potential to track AD pathology and enhance diagnostic accuracy. Furthermore, this review uniquely integrates recent findings on protein-protein interaction networks and microRNA pathways, exploring novel combinations of proteomic, genomic, and epigenomic biomarkers that provide new insights into AD’s molecular mechanisms. Additionally, we discuss the integration of these biomarkers with advanced neuroimaging techniques, emphasizing their potential to revolutionize AD diagnostics. Although large-scale validation is still needed, these biomarkers represent a critical advancement toward more accessible, cost-effective, and early diagnostic tools for AD. Full article
(This article belongs to the Special Issue Editorial Board Members’ Collection Series: “Molecular Research in Alzheimer’s Disease”)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop